We are live on ! Find out more
PBM

Propel Bio Management Portfolio holdings

AUM $191M
1-Year Est. Return 102.42%
This Fund
S&P 500
This Quarter Est. Return
+23.73%
1 Year Est. Return
+102.42%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$117M
AUM Growth
+$17.2M
Cap. Flow
+$3.07M
Cap. Flow %
2.63%
Top 10 Hldgs %
83.88%
Holding
24
New
8
Increased
4
Reduced
4
Closed
4

Top Buys

Rank Stock Value
1
VRDN icon
Viridian Therapeutics
VRDN
+$5.28M
2
KYTX icon
Kyverna Therapeutics
KYTX
+$4.95M
3
IVA
Inventiva
IVA
+$4.65M
4
OCS icon
Oculis Holding
OCS
+$3.46M
5
PHAT icon
Phathom Pharmaceuticals
PHAT
+$2.68M

Top Sells

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$10.9M
2
APLT
Applied Therapeutics
APLT
+$6.83M
3
TCRX icon
TScan Therapeutics
TCRX
+$3.52M
4
JSPR icon
Jasper Therapeutics
JSPR
+$2.45M
5
MIST icon
Milestone Pharmaceuticals
MIST
+$2.17M

Sector Composition

Rank Sector Weight
1 Healthcare 79.21%
2 Energy 20.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PAGP icon
1
Plains GP Holdings
PAGP
$5.52B
$24.4M 20.79%
1,272,360
– –
ACHV icon
2
Achieve Life Sciences
ACHV
$874M
$18.8M 16.07%
3,786,425
– –
PHAT icon
3
Phathom Pharmaceuticals
PHAT
$769M
$12.3M 10.49%
740,918
+187,991
+34% +$2.68M
VRDN icon
4
Viridian Therapeutics
VRDN
$2.6B
$8.79M 7.51%
282,531
+192,531
+214% +$5.28M
MIST icon
5
Milestone Pharmaceuticals
MIST
$149M
$8.32M 7.1%
4,118,321
-1,006,569
-20% -$2.17M
KYTX icon
6
Kyverna Therapeutics
KYTX
$510M
$6.27M 5.35%
+666,666
New +$4.95M
CMPS
7
Compass Pathways
CMPS
$1.84B
$5.95M 5.08%
861,778
+351,778
+69% +$2.15M
IVA
8
Inventiva
IVA
$1.13B
$4.65M 3.97%
+1,000,000
New +$4.65M
DCTH icon
9
Delcath Systems
DCTH
$572M
$4.43M 3.78%
438,509
– –
ABEO icon
10
Abeona Therapeutics
ABEO
$343M
$4.38M 3.74%
830,780
-143,242
-15% -$721K
CLDX icon
11
Celldex Therapeutics
CLDX
$3.12B
$4.19M 3.58%
154,300
-700
-0.5% -$18.4K
NKTR icon
12
Nektar Therapeutics
NKTR
$2.53B
$3.5M 2.99%
82,822
+33,822
+69% +$1.89M
OCS icon
13
Oculis Holding
OCS
$676M
$3.45M 2.95%
+172,839
New +$3.46M
SABS icon
14
SAB Biotherapeutics
SABS
$338M
$2.44M 2.08%
+652,881
New +$2.15M
RGNX icon
15
Regenxbio
RGNX
$590M
$1.68M 1.44%
+116,896
New +$1.46M
LONA
16
LeonaBio Inc
LONA
$71.2M
$1.13M 0.96%
149,279
– –
LENZ
17
LENZ Therapeutics
LENZ
$187M
$945K 0.81%
+59,085
New +$1.72M
AARD
18
Aardvark Therapeutics
AARD
$118M
$609K 0.52%
+46,408
New +$579K
ZVRA icon
19
Zevra Therapeutics
ZVRA
$736M
$571K 0.49%
63,683
-168,191
-73% -$1.59M
KLRS
20
Kalaris Therapeutics
KLRS
$92.8M
$355K 0.3%
+42,053
New +$269K
AKRO
21
DELISTED
Akero Therapeutics
AKRO
– –
-228,884
Closed -$10.9M
APLT
22
DELISTED
Applied Therapeutics
APLT
– –
-11,285,420
Closed -$6.83M
JSPR icon
23
Jasper Therapeutics
JSPR
$23.6M
– –
-1,028,806
Closed -$2.45M
TCRX icon
24
TScan Therapeutics
TCRX
$26.5M
– –
-1,932,304
Closed -$3.52M

Similar funds

CFG
Capital Financial Group Greenwood Village, Colorado $191M AUM
MWM
Magnolia Wealth Management Dothan, Alabama $191M AUM 17.58% 1-Year Est. Return
ALWM
Andrews Lucia Wealth Management Danville, California $191M AUM 24.94% 1-Year Est. Return
PFA
Pillar Financial Advisors Louisville, Kentucky $191M AUM 21.21% 1-Year Est. Return
LKWM
Lee-Kelleher Wealth Management Fulton, Maryland $191M AUM 28.48% 1-Year Est. Return
NWM
Navigoe Wealth Management Redondo Beach, California $191M AUM 25.21% 1-Year Est. Return
AA
Atmos Advisory Pittsburgh, Pennsylvania $191M AUM 12.84% 1-Year Est. Return
MCA
Martin Capital Advisors San Antonio, Texas $191M AUM 42.42% 1-Year Est. Return

Propel Bio Management's Q4 2025 Portfolio in Review

As of Q4 2025, Propel Bio Management held 24 positions worth $117M, up 17% from $99.9M the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Propel Bio Management's Q4 2025 filing shows 8 new, 4 increased, 4 reduced and 4 closed positions. Its largest new stake was Kyverna Therapeutics: 666,666 shares worth $6.27M. The largest sale was Akero Therapeutics, an estimated $10.9M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 77% a quarter earlier, followed by Energy.

  • Propel Bio Management's largest Q4 2025 buy was Kyverna Therapeutics: 666,666 shares worth $6.27M.
  • Propel Bio Management added most to Viridian Therapeutics in Q4 2025, an estimated $5.28M increase.
  • Propel Bio Management's biggest Q4 2025 reduction was Milestone Pharmaceuticals, cutting an estimated $2.17M.
  • Propel Bio Management fully exited Akero Therapeutics in Q4 2025, selling an estimated $10.9M.
  • Propel Bio Management's ten largest holdings make up 84% of its $117M portfolio in Q4 2025.
  • Propel Bio Management opened 8 new positions and closed 4 in Q4 2025.
  • Propel Bio Management's portfolio value rose 17% quarter-over-quarter to $117M.

Based on Propel Bio Management's 13F filing for Q4 2025, filed 11 Feb 2026.